Abstract
Purpose: The aim of this study was to compare responses to aflibercept treatment in age-based groups of patients with macular edema following branch retinal vein occlusion (BRVO). Methods: Eighty-five patients with macular edema following BRVO were divided into 4 groups according to their age: Group I (i.e., 45- to 54-year-olds), Group II (i.e., 55- to 64-year-olds), Group III (i.e., 65- to 74-year-olds), and Group IV (i.e., 75- to 84-year-olds). Each patient received a loading dose of 3 monthly intravitreal aflibercept injections. The treatment response was evaluated with visual acuity (VA) and optical coherence tomography measurements of the central foveal thickness (CFT), outer nuclear layer thickness (ONLT), and photoreceptor layer thickness (PRLT) before treatment and 1 month after the first and third injections. Results: In Group I (n = 19), Group II (n = 25), Group III (n = 23), and Group IV (n = 18), the mean values of VA, CFT, ONLT, and PRLT improved significantly 3 months after treatment. Whereas VA improved the most in Group I, its improvement significantly decreased in each progressively older age group, as did the reduction of the CFT, ONLT, and PRLT values, all of which were greater in groups I and II. Furthermore, age significantly correlated with changes in VA, CFT, ONLT, and PRLT across all groups. Conclusion: The efficacy and effectiveness of aflibercept treatment decrease in patients with macular edema following BRVO as they age, most likely due to age-related changes in posterior ocular structures.
References
1.
Jaulim
A
, Ahmed
B
, Khanam
T
, Chatziralli
IP
. Branch retinal vein occlusion: epidemiology, pathogenesis, risk factors, clinical features, diagnosis, and complications. An update of the literature
. Retina
. 2013
May
;33
(5
):901
–10
.
[PubMed]
0275-004X2.
Klein
R
, Moss
SE
, Meuer
SM
, Klein
BE
. The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study
. Arch Ophthalmol
. 2008
Apr
;126
(4
):513
–8
.
[PubMed]
0003-99503.
Sperduto
RD
, Hiller
R
, Chew
E
, Seigel
D
, Blair
N
, Burton
TC
, et al. Risk factors for hemiretinal vein occlusion: comparison with risk factors for central and branch retinal vein occlusion: the eye disease case-control study
. Ophthalmology
. 1998
May
;105
(5
):765
–71
.
[PubMed]
0161-64204.
Campochiaro
PA
, Bhisitkul
RB
, Shapiro
H
, Rubio
RG
. Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion
. Ophthalmology
. 2013
Apr
;120
(4
):795
–802
.
[PubMed]
0161-64205.
Noma
H
, Funatsu
H
, Mimura
T
, Eguchi
S
, Hori
S
. Soluble vascular endothelial growth factor receptor-2 and inflammatory factors in macular edema with branch retinal vein occlusion.
Am J Ophthalmol. 2011
;152:669-677. e661. 6.
Kuppermann
BD
, Blumenkranz
MS
, Haller
JA
, Williams
GA
, Weinberg
DV
, Chou
C
, et al.; Dexamethasone DDS Phase II Study Group
. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema
. Arch Ophthalmol
. 2007
Mar
;125
(3
):309
–17
.
[PubMed]
0003-99507.
Scott
IU
, Ip
MS
, VanVeldhuisen
PC
, Oden
NL
, Blodi
BA
, Fisher
M
, et al.; SCORE Study Research Group
. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6
. Arch Ophthalmol
. 2009
Sep
;127
(9
):1115
–28
.
[PubMed]
0003-99508.
Campochiaro
PA
, Heier
JS
, Feiner
L
, Gray
S
, Saroj
N
, Rundle
AC
, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.
Ophthalmology.2010
;117:1102-1112. e1101.9.
Campochiaro
PA
, Clark
WL
, Boyer
DS
, Heier
JS
, Brown
DM
, Vitti
R
, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study
. Ophthalmology
. 2015
Mar
;122
(3
):538
–44
.
[PubMed]
0161-642010.
Holz
FG
, Roider
J
, Ogura
Y
, Korobelnik
JF
, Simader
C
, Groetzbach
G
, et al. VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study
. Br J Ophthalmol
. 2013
Mar
;97
(3
):278
–84
.
[PubMed]
0007-116111.
Boyer
D
, Heier
J
, Brown
DM
, Clark
WL
, Vitti
R
, Berliner
AJ
, et al. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study
. Ophthalmology
. 2012
May
;119
(5
):1024
–32
.
[PubMed]
0161-642012.
Clark
WL
, Boyer
DS
, Heier
JS
, Brown
DM
, Haller
JA
, Vitti
R
, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study
. Ophthalmology
. 2016
Feb
;123
(2
):330
–6
.
[PubMed]
0161-642013.
Heier
JS
, Campochiaro
PA
, Yau
L
, Li
Z
, Saroj
N
, Rubio
RG
, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial
. Ophthalmology
. 2012
Apr
;119
(4
):802
–9
.
[PubMed]
0161-642014.
Feeney-Burns
L
, Burns
RP
, Gao
CL
. Age-related macular changes in humans over 90 years old
. Am J Ophthalmol
. 1990
Mar
;109
(3
):265
–78
.
[PubMed]
0002-939415.
Gao
H
, Hollyfield
JG
. Aging of the human retina. Differential loss of neurons and retinal pigment epithelial cells
. Invest Ophthalmol Vis Sci
. 1992
Jan
;33
(1
):1
–17
.
[PubMed]
0146-040416.
Booij
JC
, Baas
DC
, Beisekeeva
J
, Gorgels
TG
, Bergen
AA
. The dynamic nature of Bruch’s membrane
. Prog Retin Eye Res
. 2010
Jan
;29
(1
):1
–18
.
[PubMed]
1350-946217.
Salvi
SM
, Akhtar
S
, Currie
Z
. Ageing changes in the eye
. Postgrad Med J
. 2006
Sep
;82
(971
):581
–7
.
[PubMed]
0032-547318.
Matsumoto
H
, Sato
T
, Kishi
S
. Outer nuclear layer thickness at the fovea determines visual outcomes in resolved central serous chorioretinopathy.
Am J Ophthalmol.2009
;148:105-110. e101. Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology.2010;117:1124-1133. e1121. 19.
Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010 Jun;117(6):1124–33.e1.
20.
Holash
J
, Davis
S
, Papadopoulos
N
, Croll
SD
, Ho
L
, Russell
M
, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects
. Proc Natl Acad Sci USA
. 2002
Aug
;99
(17
):11393
–8
.
[PubMed]
0027-842421.
Carmeliet
P
, Moons
L
, Luttun
A
, Vincenti
V
, Compernolle
V
, De Mol
M
, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions
. Nat Med
. 2001
May
;7
(5
):575
–83
.
[PubMed]
1078-895622.
Ozsaygili
C
, Duru
Z
, Cicek
A
, Ulusoy
DM
, Demirtas
AA
, Duru
N
. THE EFFECT OF AGE ON AFLIBERCEPT (EYLEA) RESPONSE IN DIABETIC MACULAR EDEMA. Retina (Philadelphia, Pa). 2019
. Altunel O, Göktaş A, Duru N, Özköse A, Arifoğlu HB, Ataş M, editors. The effect of age on dexamethasone intravitreal implant (Ozurdex®) response in macular edema secondary to branch retinal vein occlusion. SeminOphthalmol; 2018: Taylor & Francis.23.
Altunel O, Göktaş A, Duru N, Özköse A, Arifoğlu HB, Ataş M, editors. The effect of age on dexamethasone intravitreal implant (Ozurdex®) response in macular edema secondary to branch retinal vein occlusion. Semin Ophthalmol. 2018;33(2):179–84.
24.
Le Goff
MM
, Bishop
PN
. Adult vitreous structure and postnatal changes
. Eye (Lond)
. 2008
Oct
;22
(10
):1214
–22
.
[PubMed]
0950-222X25.
Marticorena
J
, Romano
MR
, Heimann
H
, Stappler
T
, Gibran
K
, Groenewald
C
, et al. Intravitreal bevacizumab for retinal vein occlusion and early growth of epiretinal membrane: a possible secondary effect?
Br J Ophthalmol
. 2011
Mar
;95
(3
):391
–5
.
[PubMed]
0007-116126.
Oksala
A
. Ultrasonic findings in the vitreous body at various ages
. Albrecht Von Graefes Arch Klin Exp Ophthalmol
. 1978
Sep
;207
(4
):275
–80
.
[PubMed]
0065-610027.
Gisladottir
S
, Loftsson
T
, Stefansson
E
. Diffusion characteristics of vitreous humour and saline solution follow the Stokes Einstein equation
. Graefes Arch Clin Exp Ophthalmol
. 2009
Dec
;247
(12
):1677
–84
.
[PubMed]
0721-832X28.
Schindler
RH
, Chandler
D
, Thresher
R
, Machemer
R
. The clearance of intravitreal triamcinolone acetonide
. Am J Ophthalmol
. 1982
Apr
;93
(4
):415
–7
.
[PubMed]
0002-939429.
Grossniklaus
HE
, Nickerson
JM
, Edelhauser
HF
, Bergman
LA
, Berglin
L
. Anatomic alterations in aging and age-related diseases of the eye.
Invest Ophthalmol Vis Sci. 2013
;54:ORSF23-ORSF27. 30.
Kozhevnikova
OS
, Fursova
AZ
, Markovets
AM
, Telegina
DV
, Muraleva
NA
, Kolosova
NG
. VEGF and PEDF levels in the rat retina: effects of aging and AMD-like retinopathy. Advances in gerontology = Uspekhigerontologii.2018
;31:339-344.© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
